Navigation Links
Celsion Corporation to Ring the NASDAQ Stock Market Closing Bell on July 16, 2014
Date:7/14/2014

bled Expression and Secretion of RNA. With this acquisition, Celsion is now focused on the leading-edge of cancer treatment, with assets in directed chemotherapies, immunotherapies and DNA- or RNA-based therapies.

About Celsion Corporation

Celsion is fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer.  The pipeline also includes EGEN-001, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers.  Celsion has three platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlasTM, TheraSilenceTM and RASTTM.  For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.  Readers are cautioned that such forward-looking statements, including, without limitation, statements about the acquisition and the combined company as well as clinical and pre-clinical programs, involve risks and uncertainties. These risks and uncertainties include, without limitation, difficulties and operational and financial risks associated with integrating Celsion and EGEN after completion of the acquisition; unforeseen changes in the course of research and development activities and in clinical trials; the significant expense, time, and risk of failure of conducting clinical trials; the need for Celsion to evaluate its future development plans; termina
'/>"/>

SOURCE Celsion Corporation
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering
2. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials at the 2013 San Antonio Breast Cancer Conference
3. Celsion Corporation Announces Strategic Loan Facility
4. Celsion Corporation Reports Third Quarter 2013 Financial Results and Provides Business Update
5. Celsion Corporation to Hold Third Quarter 2013 Financial Results Conference Call on Tuesday, November 12, 2013
6. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials to be Presented at the 2013 San Antonio Breast Cancer Conference
7. Celsion Corporation Reports Second Quarter 2013 Financial Results and Provides HEAT Study Update
8. Celsion Corporation to Hold Second Quarter 2013 Financial Results Conference Call on Thursday, August 8, 2013
9. Celsion Corporation Issues Statement Regarding Misleading Blog Entry
10. Celsion Corporation Reports Year End 2012 Financial Results and Provides Business Update
11. Celsion Corporation to Hold Year-End 2012 Financial Results Conference Call On Monday, March 18, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (NYSE: RMD ) today announced results for its ... $423.0 million, a 10 percent increase compared to the quarter ... constant currency basis). Net income was $91.2 million, an increase ... 2013. Diluted earnings per share for the quarter were $0.64, ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015  Profil Institute for ... on diabetes and obesity, announced today a new textbook,  ... Development,  published by Springer, a leading global scientific publisher. ... analyze and illustrate techniques for use in early phase ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and Markets ... "Allergy Diagnostics Market by Allergen Source, Product & by ... their offering. The global allergy diagnostics market ... to grow at a CAGR of 12.67%, to reach $2,230.72 ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... VIVUS, Inc. (Nasdaq: VVUS ... (TA-303), a phase 3 clinical trial evaluating the safety ... treatment of erectile dysfunction (ED),will be presented this afternoon ... in Washington D.C.  The meeting is jointly sponsored by ...
... (NYSE: WPI ) today announced that its subsidiary, ... Food and Drug Administration (FDA) for Nabumetone Tablets USP, 500 ... shortly. Nabumetone had total U.S. sales of ... according to IMS Health.  Nabumetone is indicated for the relief ...
Cached Medicine Technology:Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting 2Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting 3Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting 4Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting 5Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting 6Watson's Nabumetone Tablets Receive FDA Approval 2
(Date:1/22/2015)... January 22, 2015 Deer Path of Huntley ... a Valentine’s Day Happy Hour from 3 p.m. to 4 p.m. ... Regency Parkway in Huntley, Illinois, serves adults with physical disabilities between ... will include Valentine's Day treats, games and sweetheart-themed karaoke. , For ...
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort located ... the number one best large hotel for families in the ... their annual Travelers’ Choice Awards. , TripAdvisor represents the ... home to millions of unbiased and honest traveler reviews. The ...
(Date:1/22/2015)... 2015 Angelweddingdress is a famous wedding dress ... customers to follow it on Facebook, Twitter, and Pinterest. The ... gift. Angelweddingdress draws a lottery every week. , Moreover, the ... 28, 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... 2015 A new white paper by ... person-centeredness in the long-term care environment as well as ... continuum. The paper, “The Power of Person-Centeredness in Long-Term ... practices of the patient, resident and family experience in ...
(Date:1/22/2015)... January 22, 2015 Joan Lunden, award-winning ... speaker at the upcoming 32nd Annual Miami Breast ... Physicians’ Education Resource®, LLC (PER®) , shares that “a ... gone undetected if she had not followed up her ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... PHILADELPHIA, Nov. 6 In a newly-published special supplement, ... policies to prevent and treat venous thromboembolism (VTE), a ... the world. Lippincott Williams & Wilkins (LWW) ... a disease that includes both the common medical condition ...
... Nov. 6 The American Academy of Nursing ... of Lippincott Williams & Wilkins (LWW) nursing publications ... Kluwer Health, a leading provider of information and ... medicine, nursing, allied health, and pharmacy. Academy Fellows ...
... DALLAS, Nov. 6 Lockton Benefit Group, the ... Companies, LLC, today announced employer health cost reduction ... U.S.-based healthcare company Concentra. , (Logo: ... a services provider to support Lockton,s clients with: ...
... play a role in boosting memories -- or forgetting them, ... Do you remember the first time you smelled a type ... that your brain might. , In the study, published ... researchers showed objects to adult study participants. They paired the ...
... to bronchiolitis, study finds , FRIDAY, Nov. 6 (HealthDay ... traffic as a risk factor for bronchiolitis, the respiratory ... the first year of life, a new study finds. ... appliances were more likely to show up in doctors, ...
... Researchers at Wake Forest University School of Medicine and the ... (PSA) levels in men may be caused by a hormone ... predictor of the need for a prostate biopsy. ... potential sign of prostate cancer, leading to the widespread use ...
Cached Medicine News:Health News:Journal of Cardiovascular Nursing Urges Policies and Prevention To Reduce Deaths from Venous Thromboembolism 2Health News:Journal of Cardiovascular Nursing Urges Policies and Prevention To Reduce Deaths from Venous Thromboembolism 3Health News:Seven LWW Nursing Editors Recognized as Leaders by American Academy of Nursing 2Health News:Seven LWW Nursing Editors Recognized as Leaders by American Academy of Nursing 3Health News:Lockton and Concentra Working Together to Lower Healthcare Costs for Employers 2Health News:Lockton and Concentra Working Together to Lower Healthcare Costs for Employers 3Health News:New Smells 'Etched' in Brain: Study 2Health News:Wood Fires Can Harm the Youngest Lungs 2Health News:New finding suggests prostate biopsy is not always necessary 2Health News:New finding suggests prostate biopsy is not always necessary 3
... The EndoProbe handpieces, used for endophotocoagulation ... aspiration, 25 gauge, and illuminating models. ... the ophthalmologist with uncompromised laser treatment ... 3-meter, fiber-optic cables that are flexible ...
... The Rare Earth Intraocular Magnet is especially ... intraocular foreign bodies. The precise, sleek design ... commonly observed with electromagnetic devises. Due to ... minimizes the possibility of secondary foreign body ...
... On-line Electronic Help (OLEH), an ... to critical anesthesia-related information. OLEH brings ... need it most right on ... care of the patient and ...
... High-performance monitoring for flexible care settings., ... monitors combine portability and measurement flexibility ... needs of intermediate care environmentsat the ... strong heritage in patient monitoring, IntelliVue ...
Medicine Products: